Related references
Note: Only part of the references are listed.Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii et al.
CANCER RESEARCH (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Maria Martinez-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia
Alessia Bottos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Gregory J. Riely et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
Amelie Marquette et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Florian A. Karreth et al.
CANCER DISCOVERY (2011)
Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
Apostolia Maria Tsimberidou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Raf-1 Addiction in Ras-Induced Skin Carcinogenesis
Karin Ehrenreiter et al.
CANCER CELL (2009)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. M. Smalley et al.
ONCOGENE (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
BRAF V600E disrupts AZD6244-Induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins
Bret B. Friday et al.
CANCER RESEARCH (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
K. S. M. Smalley et al.
BRITISH JOURNAL OF CANCER (2007)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Chemotherapy and targeted therapy combinations in advanced melanoma
KT Flaherty
CLINICAL CANCER RESEARCH (2006)
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett et al.
MOLECULAR CELL (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf
T Brummer et al.
ONCOGENE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)